We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Blood Test Helps Identify Patients with Alzheimer's Associated Amyloid Pathology

By LabMedica International staff writers
Posted on 31 Jan 2025
Print article
Image: The U.S. FDA has granted Breakthrough Device Designation to the Access p‑Tau217/β-Amyloid 1-42 plasma ratio Test (Photo courtesy of Beckman Coulter)
Image: The U.S. FDA has granted Breakthrough Device Designation to the Access p‑Tau217/β-Amyloid 1-42 plasma ratio Test (Photo courtesy of Beckman Coulter)

Neurological diseases, such as Alzheimer's disease, are becoming an increasing cause of death and disability among older adults worldwide, posing significant challenges to healthcare systems. These conditions are complex and diverse, presenting a range of symptoms that complicate diagnosis. To address these challenges, a new blood test has been developed to help healthcare providers detect amyloid pathology associated with Alzheimer’s disease.

The Access p‑Tau217/β-Amyloid 1-42 plasma ratio, developed by Beckman Coulter Diagnostics (Brea, CA, USA), is a blood test that measures the ratio of phosphorylated tau protein (p-Tau217) and β‑Amyloid 1-42, both of which are key biomarkers involved in the neurodegenerative processes of Alzheimer's disease. This blood-based in vitro diagnostic (IVD) test is capable of quantifying these biomarkers in plasma, providing a non-invasive, accessible, and earlier method to detect Alzheimer’s-related pathology. Early detection is crucial for improving diagnosis, enabling timely interventions, and identifying patients for therapeutic trials, all of which can help accelerate progress in Alzheimer’s research and treatment. The Access p‑Tau217/β-Amyloid 1-42 plasma ratio has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

"We are honored to receive Breakthrough Device Designation from the U.S. FDA for our p‑Tau217/β-Amyloid 1-42 assay, a significant step forward in addressing the urgent need for earlier and more accurate detection of Amyloid pathology, a hallmark of Alzheimer's disease," said Kathleen Orland, Senior Vice President, General Manager, Clinical Chemistry and Immunoassay for Beckman Coulter Diagnostics. "This designation reflects the potential of our test to transform how Alzheimer's disease is diagnosed and managed, ultimately leading to improved outcomes for patients and families affected by this devastating disease."

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
New
Epstein-Barr Virus Assay
Panther Fusion EBV Quant Assay
New
Salmonella Infection Rapid Test
HumaTex Salmonella

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.